Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B

Aliment Pharmacol Ther. 2022 Sep;56(5):916-917. doi: 10.1111/apt.17117.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Adenine / adverse effects
  • Alanine
  • Bone Density
  • Fumarates
  • Hepatitis B, Chronic* / drug therapy
  • Humans
  • Kidney / physiology
  • Tenofovir / adverse effects
  • Tenofovir / analogs & derivatives

Substances

  • Fumarates
  • Tenofovir
  • tenofovir alafenamide
  • Adenine
  • Alanine